Development of a screening assay for novel chemical inhibitors of Chlamydia trachomatis growth.

The data underlying S1 and S2 Figs. (A) Resorufin fluorescence at different HeLa cell seeding densities. Data are displayed in S1B Fig. (B) GFP fluorescence at different infection doses. Data are displayed in S1C Fig. (C) Host cell viability (via resorufin fluorescence) at different infection doses. Data are displayed in S1D Fig. (D) DMSO tolerance of CTL2-GFP and HeLa cells, as measured by GFP and resorufin fluorescence, respectively. Data are displayed in S1F Fig. (E) Plate uniformity and signal variability of the bacterial growth inhibition assay, based on measuring GFP fluorescence derived from CTL2-GFP. Replicate 1 is displayed in S1G Fig. (F) Plate uniformity and signal variability of the host cell viability assay, based on measuring resorufin fluorescence. Replicate 1 is displayed in S1H Fig. (G) Eight clinical antibiotics tested for bacterial growth inhibition and host cell viability with the bulk fluorescence readouts of the screening assay protocol. Data displayed in S2A Fig. (H) MICs of eight antibiotics as determined in this study and compared with previously reported data. Data displayed in S2B Fig. (XLSX)